Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAPClears the way to ...

Biodexa Pharmaceuticals (BDRX) announced the results of its Type C meeting with the U.S. Food and Drug Administration, FDA, regarding the ...

Nationally recognized pediatric gastroenterologist, Michael Dolinger, MD, MBA, joins Hassenfeld Children's Hospital at NYU Langone as director of the Pediatric Inflammatory Bowel Disease Program ...

Children who frequently miss school because of abdominal complaints are far more likely to be suffering from disorders of the gut-brain axis such as irritable bowel syndrome than diseases that can be ...